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SulTlnlary 
Immunization  with  defined  tumor antigens  is currently  limited to a  small number of cancers 
where  candidates  for tumor rejection  antigens  have been  identified.  In this  study we investi- 
gated whether pulsing dendritic  cells (DC) with tumor-derived P,.NA is an effective way to in- 
duce  CTL  and  tumor  immunity.  DC  pulsed  with  in  vitro  synthesized  chicken  ovalbumin 
(OVA)  P, NA  were  more  effective  than  OVA  peptide-pulsed  DC  in  stimulating  primary, 
OVA-specific  CTL responses in vitro.  DC pulsed with unfractionated  P,  NA (total or polyA  +) 
from OVA-expressing tumor cells were as effective as DC pulsed with OVA peptide at stimu- 
lating  CTL  responses.  Induction  of OVA-specific  CTL  was  abrogated  when  polyA  +  P,.NA 
from OVA-expressing cells was treated with an OVA-specific  antisense  oligodeoxynucleotide 
and P,.Nase  H,  showing  that sensitization  of DC was indeed  mediated by OVA P,.NA.  Mice 
vaccinated  with  DC  pulsed  with  P,  NA  from  OVA-expressing  tumor  cells  were  protected 
against a challenge with OVA-expressing tumor cells. In the poorly immunogenic, highly meta- 
static, B16/F10.9  tumor model a dramatic reduction  in lung metastases was observed in mice 
vaccinated  with  DC  pulsed  with  tumor-derived  P, NA  (total  or  polyA  +,  but  not  polyA- 
P,.NA).  The finding  that RNA  transcribed  in vitro from cDNA  cloned in a bacterial plasmid 
was highly effective in sensitizing DC shows that amplification of the antigenic content from a 
small number of tumor cells is feasible, thus expanding the potential use of P,.NA-pulsed  DC- 
based vaccines for patients bearing very small, possibly microscopic, tumors. 
T 
he dendritic  cell (DC) 1 network is a specialized system 
for presenting  Ag  to  naive  or  quiescent  T  cells,  and 
consequently  plays a central role in the induction  of T  cell 
and B  cell immunity in vivo  (1).  Consistent  with  this  no- 
tion, several studies have documented  the exceptional abil- 
ity of DC  to  stimulate  naive  CD4 +  and  CD8 +  T  cells in 
vitro and in vivo (1).  Immunization using DC loaded with 
tumor antigens may therefore represent a potentially pow- 
erful method of inducing  antitumor immunity.  Indeed, re- 
cent  studies  have  shown  that  vaccination  with  dendritic 
cells  pulsed  with  specific  antigens  in  the  form  of protein 
(2-5)  or  peptide  (5-9)  were  capable  of priming  CTL  in 
mice and engendering tumor immunity. 
Immunization  with  defined  tumor  antigens  is currently 
limited  to  a  small  number  of cancers  in  which  candidates 
for tumor rejection  antigens  have been identified  (10,  11). 
Furthermore, it is unclear whether or which of the recently 
identified  human  tumor-specific  or tumor-associated  anti- 
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gens are the  best choice  to mount  an effective anti-tumor 
immune response in vivo, an issue  whose  resolution  must 
await  clinical  studies.  This  potential  concern  was  under- 
scored in a report by Anichini  et al.  who have shown that 
the  majority of CTL present in HLA-A2.1  melanoma pa- 
tients  were  not  directed  to  the  recently  identified  tumor 
antigens, Melan-A/Mart-1,  tyrosinase, gpl00,  or MAGE-3 
(12).  This  study  suggested  that  immunization  with  other, 
yet unidentified,  antigens would be more effective in elicit- 
ing tumor immunity in these patients.  In addition,  a recent 
study  by Johnston  et  al.  has  demonstrated  that  improved 
immunogenicity  of tumor  cells  engineered  to  express  the 
B7-1  gene was caused by expansion of the antigenic reper- 
toire  of the  tumor thereby implying that vaccination with 
multiple  tumor antigens  may be superior to using a  single 
dominant epitope (13). 
An alternative  approach, not encumbered by these limi- 
tations,  is  to  use  unfractionated  tumor peptides  or  tumor 
proteins  as  a  source  of tumor  antigen.  Two  studies  have 
shown  that  vaccination  of mice  with  splenic  antigen-pre- 
senting  cells  (APC)  or  with  epidermal  Langerhans  cells 
pulsed  with  tumor  fragments  were  capable  of inducing 
protective  immunity  against  a  tumor  challenge  (14,  15). 
More recently, Zitvogel et al. have shown that vaccination 
of mice  with  bone  marrow-derived  DC  pulsed  with  un- 
465  J. Exp. Med. ￿9  The Rockefeller University Press ￿9 0022-1007/96/08/465/08  $2.00 
Volume 184  August 1996  465-472 fractionated  tumor  peptides  was  capable  of reducing  the 
growth  of  subcutaneously  established,  weakly  immuno- 
genic tumors (16). 
There are, however, three potential drawbacks in vacci- 
nating  cancer  patients  with  unfractionated  tumor  derived 
peptides or proteins, as compared to using purified antigens. 
First,  immunization  with  unfractionated  tumor  material 
may be less effective due to the low concentration of effec- 
tive tumor antigens in the mixture, a possibility which has 
not yet been  evaluated. Second, use  of unfractionated tu- 
mor material as a source of tumor antigen will depend on 
the availability of substantial amounts  of tumor tissue from 
the patient. This is a serious limitation of a practical nature 
because a large segment of cancer patients have only small, 
often microscopic tumor burdens.  A  third potential draw- 
back is that vaccinating with unfractionated tumor derived 
antigens could induce autoimmune responses directed against 
"self" antigens (17,  18). 
One  approach  to  overcome  the  drawbacks  stemming 
from  the  use  of unfractionated  tumor  antigens  is  to  use 
messenger tLNA  (mtLNA) from tumor cells as a source of 
antigen, mRNA  can be amplified from a very small num- 
ber of cells, permitting the generation of sufficient amounts 
of  antigen  from  microscopic  amounts  of  tumor  tissue. 
Moreover,  tumor-specific tLNA  can be  enriched by sub- 
tractive hybridization with tLNA from normal tissue. This 
will increase the concentration of the relevant tumor-spe- 
cific antigen(s) and hence the potency of the vaccine. More 
importantly,  this  will  reduce  the  concentration  of non- 
tumor specific antigens or possibly self-antigens and lessen 
the potential for autoimmunity. 
Recent  studies  by  Martinon  et  al.  have  demonstrated 
priming of virus-specific CTL in mice immunized with li- 
posome  encapsulated  in  vitro  synthesized  RNA  corre- 
sponding to the influenza nucleoprotein (19).  Conry et al. 
were able to elicit antibodies in mice after intramuscular in- 
jection of in vitro synthesized P,  NA corresponding to  the 
human  carcinoembryonic  antigen  (CEA)  (20).  Most  re- 
cently, Quiet  al. have  used a  gene  gun  to  deliver human 
alpha-l-antitrypsin (HAAT) mP, NA into the epidermis of 
mice to elicit an anti-HAAT antibody response (21). 
In the current study we tested whether pulsing dendritic 
cells with tLNA is an effective way to induce CTL responses 
and tumor immunity. We used two very stringent experi- 
mental systems to assess  the antigen presenting function of 
DC  pulsed with  lkNA;  induction  of a  primary  CTL  re- 
sponse  in  vitro  and  regression  of spontaneous  lung  me- 
tastases in vivo. 
There have been few reports of primary CTL induction 
in vitro and these were achieved only by using professional 
APC  such  as  dendritic  cells  (22,  23),  or  non-professional 
APC  engineered to  display high  densities of specific pep- 
tide epitopes on the cell surface  (24,  25).  Induction of tu- 
mor  immunity  was  investigated in  the  B16/F10.9  mela- 
noma tumor system which was developed by Porgador and 
his  colleagues  and  constitutes  a  highly  relevant  model  to 
evaluate tumor vaccines  (26).  In this particular model one 
measures the efficacy of various vaccine strategies to elimi- 
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nate preexisting lung metastases in animals whose primary 
tumor was surgically removed. The only treatment that has 
shown  significant  therapeutic  benefit  in  this  model  was 
vaccination with B16/F10.9 cells transduced with both the 
IL-2 and H-2K  b genes (27).  As is the case for most human 
tumors,  no tumor-specific antigens have been identified in 
the B16/F10.9 system. 
In  this  study we  show  that  DC  pulsed with  RNA  are 
highly  potent  APC,  capable  of stimulating primary  CTL 
responses  in  vitro  which  were  equal  to  or  more  efficient 
than those elicited by peptide pulsed DC. Moreover, treat- 
ment of tumor bearing mice with DC pulsed with tumor- 
derived lkNA led to a  dramatic reduction in the extent of 
lung metastasis. 
Materials  and Methods 
Mice 
7-8-wk-old C57BL/6  mice  (H-2  b)  were  obtained from  the 
Jackson Laboratory (Bar Harbor, ME). In conducting the research 
described in this paper, the investigators adhered to the "Guide 
for the Care and Use of Laboratory Animals" as proposed by the 
committee on care of Laboratory Animal Resources Commission 
on Life Sciences, National Research Council. The facilities at the 
Duke vivarium are fully accredited by the American Association 
for Accreditation of Laboratory Animal Care. 
Cell Lines 
The F10.9 clone of the B16 melanoma of C57BL/6 origin is a 
highly metastatic, poorly immunogenic and a low class I express- 
ing cell line. F10.9/K1 is a poorly metastatic and highly immuno- 
genie  cell line derived by  transfecting F10.9  cells  with  H-2K  t' 
cDNA (26). RNIA and PdVIA-S cells are derived from the P,  auscher 
leukemia virus-induced T  cell lymphoma RBL-5  of C57BL/6 
(H-2  b)  origin (28).  Other  cell lines used were  EL4  (C57BL/6, 
H-2  b, thymoma), E.G7-OVA (EL4 cells transfected with the cDNA 
of chicken  ovalbumin  (OVA)  (29).  Cells  were  maintained  in 
DMEM supplemented with 10% fetal calf serum (FCS), 25  mM 
Hepes, 2 mM L-glutamine, and  1 mM sodium pyruvate. E.G7- 
OVA cells were maintained in medium supplemented with 400 
Izg/ml G418  (GIBCO BRL,  Gaithersburg, MD)  and F10.9/K1 
cells were maintained in medium containing 800  Izg/ml G418. 
Antigen-presenting Cells (APC) and Responder T Cells 
Splenocytes  obtained  from  naive  C57BL/6  females  were 
treated with ammonium chloride Tris buffer for 3 rain at 37~  to 
deplete red blood cells.  Splenocytes (3 ml)  at 2  ￿  10  v cells/nil 
were layered over 2 nil metrizamide gradient colunm (Nycomed 
Pharma AS, Oslo, Norway; analytical grade, 14.5 g added to 100 
ml PBS, pH 7.0)  and centrifuged at 600g for 10 rain. The DC- 
enriched fraction from the interface was further enriched by ad- 
herence for 90 min. Adherent cells (nmstly DC and a few con- 
taminating Mo) were retrieved by gentle scraping and subjected 
to a second round of adherence at 37~  for 90 min to deplete the 
contaminating Mo.  Non-adherent  cells  were  pooled as  splenic 
DC and FACS  |  analysis showed ~80-85%  DC by staining with 
mAb 33D1,  1-2% Mo by staining with mAb F4/80, 10% T cells, 
and <5% B Cells (data not shown). The pellet was resuspended 
and enriched for Mo by two rounds of adherence at 37~  for 90 
rain each. More than 80% of the adherent population was identi- 
fied as Mo by FACS  |  analysis  with  5% lymphocytes and  <5% DC. B  cells were separated  from the nonadherent  population  (B 
and T  ceils) by panning  on anti-Ig-coated plates.  The separated 
cell population which was comprised of >80% T  lymphocytes by 
FACS  |  analysis  was used as responder T  cells. 
Isolation of Total and PolyA + Cellular RNA 
Total RNA was  isolated from actively growing tissue  culture 
cells as previously described (30).  Briefly, 10  v cells were lysed in 1 
ml of guanidinium isothiocyanate (GT) buffer (4 M  guanidinium 
isothiocyanate, 25 mM sodium citrate, pH 7.0; 0.5% sarcosyl, 20 
mM EDTA, 0.1  M  2-mercaptoethanol).  Samples were vortexed 
followed by sequential addition of 100 ILl 3M sodium acetate, 1 ml 
water  saturated  phenol  and  200  Ixl chloroform/isoamyl alcohol 
(49:1).  Suspensions were vortexed and placed on ice for 15  min. 
The tubes were centrifuged at  10,000 g, 4~  for 20 min and the 
supernatant  was  carefully  transferred  to  a  fresh  tube.  An  equal 
volume of isopropanol was added and the samples were placed at 
-20~  for at least  1 h.  RNA  was  pelleted by centrifugation  as 
above.  The  pellet was  resuspended  in 300  Izl GT buffer which 
was then transferred to a microcentrifuge tube.  RNA was repre- 
cipitated by adding an  equal volume of isopropanol and placing 
the tube at  -20~  for at least 1 h. Tubes were microcentrifuged 
at high speed at 4~  for 20 rain. Supernatants were decanted and 
pellets were washed once with 70% ethanol. Pellets were allowed 
to dry at RT and then resuspended in TE (10 ~  Tris-HC1, 1 m/Vl 
EDTA, pH 7.4).  Possible contaminating  DNA was  removed by 
incubating RNA  in  10  mM MgC12,  1 mM DTT and  50  U/ml 
RNase free DNase (Boehringer-Mannheim,  Indianapolis, IN) for 
15  rain  at  37~  The  solution  was  adjusted  to  10  mM Tris,  10 
mM EDTA, 0.5% SDS and  1 mg/ml Pronase  (Boehringer-Mann- 
helm) followed by incubation at 37~  for 30 rain.  Samples were 
extracted  once  with  phenol-chloroform  and  once  with  chloro- 
form,  and  RNA  was  then  reprecipitated  in  isopropanol  at 
-20~  After centrifugation  the pellets were washed  with  70% 
ethanol,  air dried,  and  resuspended  in sterile water.  Total RNA 
was quantitated by measuring OD at 260 and 280 nm.  OD 260/ 
280  ratios were typically  1.65-2.0.  RNA  was  stored at  -70~ 
PolyA  + RNA was either isolated from total RNA using Oligotex 
(Qiagen, Chatsworth, CA) or directly from tissue culture cells us- 
ing the Messenger RNA Isolation kit (Stratagene, La Jolla, CA) as 
per manufacturer's protocols. 
Production of In  Vitro Transcribed (IVT) RNA 
Chicken ovalbumin cDNA in pUC18 was kindly provided by 
Dr.  Barry  T.  Rouse  (University of Tennessee,  Knoxville). The 
1.9-kb EcoRl fragment containing the coding region and 3' un- 
translated  region was  cloned  into  the  EcoR1  site  of pGEM4Z 
(Promega,  Madison,  WI).  Clones  containing  the  insert  in both 
the sense and anti-sense orientations were isolated and large scale 
plasmid preparations  were made using Maxi Prep Kits (Qiagen). 
Plasmids were linearized with BamH1  for use as templates for in 
vitro transcription. Transcription was carried out at 37~  for 3-4 h 
using the SP6  MEGAscript In vitro Transcription Kit (Ambion, 
Austin, TX)  per manufacturer's  protocol and adjusting the GTP 
concentration to 1.5 mM and including 6 mM mTG(5')ppp(5')G 
cap  analogue  (Ambion).  Template  DNA  was  digested  with 
RNase free DNase I and RNA was recovered by phenol/chloro- 
form and chloroforua extraction followed by isopropanol precipi- 
tation.  RNA was pelleted by microcentrifugation and the pellet 
was washed once with 70% ethanol. The pellet was air-dried and 
resuspended in sterile water. 
RNA was incubated for 30 min at 30~  in 20 mM Tris-HC1, 
pH 7.0,  50 mM KCI, 0.7 mM MnC12,  0.2 mM EDTA,  100  ~g/ 
ml acetylated BSA,  10%  glycerol,  1  mM ATP and  5,000  U/ml 
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yeast poly(A) polymerase (United States Biochemical, Cleveland, 
OH). The capped,  potyadenylated RNA was recovered by phe- 
nol/chloroform  and  chloroform  extraction  followed by  isopro- 
panol  precipitation.  RNA  was  pelleted  by  microcentrifugation 
and the pellet was washed once with 70% ethanol. The pellet was 
air-dried and resuspended in sterile water. RNA was quantitated 
by measuring OD at 260 and 280 nm and stored at -70~ 
Otigodeoxynucleotide Directed Cleavage of 0 VA mRNA 
by RNase H 
The procedure used for RNase H  site-specific cleavage ofoval- 
bumin mlLNA was essentially as previously described with minor 
modifications  (31).  Briefly,  5-10  ~g  mRNA  from  E.G7-OVA 
cells was suspended in 20 mM Hepes, pH 8.0, 50 mM KC1, 4 mM 
MgC12,  1 mM DTT, 50 I~g/ml BSA and 2 ~M of either the oli- 
godeoxynucleotide 5'-CAG TTT TTC  AAA GTT  GAT TAT 
ACT-3' which hybridizes to a sequence in OVA mRNA encod- 
ing the  CTL  epitope  SIINFEKL  or  5'-TCA TAT  TAG  TTG 
AAA CTT TTT GAC-3' (Oligos, Etc., Wilsonville, OR) which 
serves as a negative control. The samples were heated to 50~  for 
3  min  followed by  incubation  at  37~  for  30  min.  RNase  H 
(Boehringer-Mannheim)  was  added  at  10  U/ml  and  digestion 
was for 30 min at 37~  RNA was recovered by phenol/chloro- 
form and chloroform extraction followed by isopropanol precipi- 
tation.  RNA was pelleted by microcentrifugation and the pellet 
was washed once with 70% ethanol. The pellet was air-dried and 
resuspended in sterile water. Cleavage of OVA mRNA was con- 
firmed by oligo dT primed reverse transcription of test and con- 
trol samples followed by PCR with OVA-specific primers which 
flank the cleavage site (data not shown).  PCR with actin-specific 
primers was used to control between test and control samples. 
Pulsing of Antigen-presenting Cells 
Pulsing of DC with RNA was routinely performed in serum- 
free  Opti-MEM  medium  (GIBCO  BRL).  APC  were  washed 
twice in Opti-MEM  medium.  Cells were resuspended  in Opti- 
MEM  medium  at  2-5  ￿  106  cells/ml  and  added  to  15  ml 
polypropylene tubes (Falcon). The cationic lipid, DOTAP, (Boeh- 
ringer Mannheim) was used to deliver RNA into cells (32).  RNA 
(in 250-500  btl Opti-MEM medium)  and DOTAP  (in 250-500 
ILl Opti-MEM medium) was mixed in 12  ￿  75-mm polystyrene 
tubes  at  room  temperature  (RT)  for  20  min.  The  amount  of 
polyA + RNA or IVT RNA used was 5 ~g and the amount of to- 
tal RNA used was 25  /.tg. The RNA to DOTAP ratio was  1:2. 
The complex was added to the APC (2-5  ￿  106 cells)  in a total 
volume of 2 ml and incubated at 37~  in a water-bath with occa- 
sional  agitation  for  2-4  h.  The  cells were  washed  and  used  as 
stimulators for primary CTL induction in vitro. 
The  synthetic  peptide  encoding the  CTL epitope  in  chicken 
ovalbumin OVA, aa 257-264  SIINFEKL (H-2K  h)  (33)  was used 
for peptide pulsing. Peptide was purchased with unblocked (free) 
amino and carboxyl ends from Research  Genetics (Birmingham, 
AL). Peptides were dissolved in serum-free IMDM and stored at 
-20~ 
Induction of CTL In  Vitro and Cytotoxicity Assay 
T  cells (5  ￿  106  cells/ml) and  RNA  or peptide  pulsed APC 
(2.5  ￿  10  s cells/ml) were cultured in IMDM with 10% FCS, 1 mM 
sodium  pyruvate,  100  IU/ml penicillin,  100  mg/ml streptomy- 
cin,  and  5  X  10 -5  M  [3-mercaptoethanol  in 96-well U-bottom 
plates to give R/S ratio of 20:1.  After 5 d  the cells were used as 
effectors in a standard 4-h europium release assay. 
5-10  ￿  106 target cells were labeled with europium diethylene- 
triamine pentaacetate for 20 rain at 4~  After several washes,  104 europium-labeled targets  and serial dilutions of effector  cells at 
various effector/target  ratios were incubated in 200 I*l of RPMI 
1640 with 10% heat-inactivated FCS in 96-well V-bottom plates. 
The plates were centrifuged at 500 g for 3 min and incubated at 
37~  and 5% CO  2 for 4 h. 50 btl of the supernatant was harvested 
and europium release was measured by time resolved fluorescence 
(Delta fluorometer; Wallac  Inc., Gaithersburg,  MD)  (34). Spon- 
taneous release  was  less than 25%. Standard  errors  (SE) of the 
means of triplicate cultures were less than 5%. 
Immunotherapy 
E.G7-OVA Model.  C57BL/6  mice  were  immunized once 
with irradiated,  RNA-pulsed APC (2 ￿  10  ~' cells/mouse) or 5 ￿ 
1()  r  E.G7-OVA or EL4  cells. 10-14 d post-immunization mice 
were challenged  with 2  ￿  10  v live E.G7-OVA cells subcutane- 
ously in the scapular region. Mice were monitored on a regular 
basis for tumor growth and size. Mice with tumor sizes >3.5 cm 
were killed. All survivors were killed 40 d post-challenge. 
FlO.9-B16Melanoma Model.  Mice  were  injected intrafoot- 
pad with 2 ￿  10  s F10.9 cells. The post-surgical protocol was used 
as described previously with a few modifications  (27). Legs were 
amputated when the local tumor in the footpad  was 7-8 mm in 
diameter.  Post-amputation mortality was less than 5%. 2 d post- 
amputation mice were immunized intraperitoneally followed by 
weekly vaccinations twice,  for a total of three vaccinations.  Mice 
were killed based on the metastatic death in the non-immunized 
or  control groups  (28-32  d  post-amputation). Metastatic  loads 
were assayed by weighing the lungs. 
Statistical Methods 
In the B16 melanoma model, the different experimental groups 
within the  study were  compared using the Kruskal-Wallis  test. 
Comparisons of significance  for  differences  in lung weights  be- 
tween specific pairs of groups were then compared by the Mann- 
Whitney U-test. A probability of less than 0.05  (P <0.05)  was 
used for statistical significance. 
Results 
Induction of Primary OVA-specific CTL Responses In  Vitro 
Using Dendritic Cells Pulsed with  Chicken Ovalbumin RNA. 
Splenic DC  derived from C57BL/6  (H-2K  b)  mice pulsed 
with RNA were tested for their ability to induce a primary 
CTL  response  in vitro in the  E.G7-OVA tumor system. 
E.G7-OVA cells are derived from the EL4 tumor cell line 
(H-2K  b haplotype) by transfection with the chicken oval- 
bumin cDNA  (29).  The chicken ovalbumin protein con- 
tains a  single dominant epitope  (amino acids 257-264)  in 
C57BL/6 mice (33). 
Our primary aim was to determine whether RNA could 
be used to enable DC to present antigen to CD8 + T  cells. 
Accordingly,  splenic  DC  were  isolated  from  C57BL/6 
mice and pulsed with OVA peptide (amino acids 257-264) 
or with 5 txg of ovalbumin RNA synthesized in vitro (IVT 
OVA RNA) from a plasmid encoding the chicken ovalbu- 
rain cDNA. Based on preliminary studies to  optimize the 
ratio of RNA to lipid, a ratio of l:2 was used in all experi- 
ments (data not shown). The pulsed DC were used to stim- 
ulate an OVA-specific, primary CTL response in vitro. As 
shown in Fig.  1, both OVA peptide and IVT OVA RNA 
pulsed DC were capable of inducing OVA-specific primary 
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Figure 1.  Primary  OVA-specific  CTL induction in vitro with dendritic 
cells pulsed with RNA.  DC were pulsed with total RNA or polyA  + 
RNA isolated from E.G7-OVA or EL4 cells, or with IVT OVA RNA, in 
the presence of the cationic lipid DOTAP as described in Materials and 
Methods. 2 ￿  106 DC were pulsed  with either 25 btg of total RNA or 5 ~g 
of polyA  + RNA or IVT OVA RNA.  DC pulsed with OVA peptide 
were used as positive  controls. DC and naive  T cells  were incubated  for 5 d 
at a R/S of 20:1. Viable  lymphocytes  were harvested and the CTL activ- 
ity determined in a europium release assay. E.G7-OVA and EL4 cells 
were used as targets. This experiment  was repeated three times with sinai- 
lar results. 
CTL  responses,  although  RNA  pulsed  DC  were  consis- 
tently more  effective than peptide-pulsed DC  (Fig.  1 and 
data  not  shown).  To  test  whether  RNA  isolated  from 
E.G7-OVA cells was  capable of sensitizing DC  to  induce 
primary, OVA-specific CTL, total RNA or polyA  + RNA 
was isolated from E.G7-OVA or EL4  cells and incubated 
with DC.  2  ￿  106 DC were pulsed with either 25  b~g of 
total  RNA  or  5  I.tg  of polyA  +  RNA  in the  presence  of 
DOTAP as described in Materials and Methods. As shown 
in  Fig.  1,  DC  pulsed  with  either  total  or  polyA  +  RNA 
from E.G7-OVA but not from EL4  cells were  capable of 
inducing potent OVA-specific CTL response, comparable 
to  that  obtained with DC  pulsed with the  OVA peptide. 
Stimulation of a  CTL response by  (total  or polyA  +)  EL4 
RNA pulsed DC was low and similar on E.G7-OVA and 
EL4  targets  (Fig.  1),  reflecting the  immunodominance of 
the  OVA  epitope  and the  relative weakness  of the  EL4- 
encoded antigens. 
Fig. 2 demonstrates that total as well as polyA  +, but not 
polyA-, RNA isolated from E.G7-OVA cells is capable of 
sensitizing DC  to  stimulate a  primary CTL  response.  To 
prove that sensitization of De  is indeed mediated by RNA 
encoding chicken OVA,  polyA  +  RNA  from E.G7-OVA 
cells was incubated with either an antisense oligonucleotide 
spanning the  sequence  encoding  the  known  H-2K  ~  re- 
stricted  CTL  epitope  present  in  the  chicken  ovalbumin 
gene or with a control oligodeoxynucleotide, followed by 
RNase  H  treatment  to  remove  any  RNA  sequence  to 
which the oligodeoxynucleotide probe had hybridized. As 
shown in Fig. 2, induction of primary, OVA-specific CTL 
responses was abolished when the polyA  + RNA was incu- 
bated with the antisense, but not with the control, oligode- 
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Figure 2.  Sensitization of total E.G7-OVA RNA pulsed DC for stimu- 
lation of OVA-specific  CTL responses is mediated by the polyA  + OVA- 
specific  RNA.  DC  were  pulsed  with  total  RNA,  polyA-- RNA  or 
polyA  + RNA in the presence of DOTAP and cultured with naive T cells 
in 96-well U-bottom plates for 5 d.  The polyA + RNA fraction  from 
E.G7-OVA cells was treated with an ant￿9  oligodeoxynucleotide  cor- 
responding  to the CTL epitope encoding region of the OVA gene or a 
control oligodeoxynucleotide  followed by RNase H  treatment  to elimi- 
nate  the hybridized  RNA. DC pulsed with OVA peptide  was used  to 
compare the efficacy of the various groups. E.G7-OVA, EL4, and RMA-S 
cells pulsed with OVA peptide were used as targets. 
oxynucleotide.  Generation  of OVA-specific CTL  responses 
was  tested  on  E.G7-OVA  cells,  endogenously  expressing 
the  ovalbumin  gene,  and  RMA-S  cells  pulsed  with  the 
dominant  OVA  CTL  epitope.  Fig.  2  demonstrates  that 
CTL  generated by DC  pulsed with total or polyA  §  E.GT- 
OVA  RNA  lysed both  targets to  a  similar extent.  This in- 
dicates  that  the  epitope  presented  by  E.GT-OVA  RNA 
pulsed  DC  corresponds  to  the  previously  defined  single 
dominant  CTL  epitope encoded in the chicken ovalbumin 
gene.  However,  DC  pulsed  with  peptide-stimulated  CTL 
lysed  the  RMA-S/OVA  peptide  targets  more  efficiently 
than the E.GT-OVA  targets,  suggesting that  the CTL  gen- 
erated by DC pulsed with the OVA peptide may have been 
of lower affinity than CTL  generated by RNA-pulsed  DC, 
consistent with the findings of Carbone  et al.  (35). 
Fig.  3  shows  that  DC  pulsed with  IVT  OVA  RNA  are 
more  potent  than  macrophages  (Mo)  pulsed  with  IVT 
OVA  RNA  at  stimulating  primary  CTL  responses.  Fig.  3 
also demonstrates  the requirement for DOTAP  in facilitat- 
ing sensitization of DC  with RNA. 
Induction of Anti-Tumor Immunity by DC Pulsed with  Tu- 
mor RNA.  We  next  tested  whether  vaccination  of mice 
with OVA  RNA  pulsed DC  was capable of providing pro- 
tection against E.GT-OVA  tumor  cells. Mice were immu- 
nized once with 2  ￿  106 RNA-pulsed  DC  or with 5  ￿  106 
irradiated E.G7-OVA  cells and  10 d  later,  mice were chal- 
lenged  with  a  tumorigenic  dose  of E.GT-OVA  cells.  Ap- 
pearance and size of the tumor were determined on a regular 
basis.  Fig.  4  shows the  size of the  tumors  37  d  post-tumor 
implantation.  The  average  tumor  size in  mice  immunized 
with irradiated  EL4  cells was  25  cm while the  average tu- 
40 
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Figure 3.  RNA pulsed DC are more effective than Mo at stimulating 
primary,  OVA-specific  CTL responses in vitro.  DC or Mo were pulsed 
with IVT OVA RNA in the presence  or absence of the cationic  lipid, 
DOTAP. Naive T  cells were cultured  with pulsed APC for 5 d and the 
viable cells harvested for a CTL assay. E.G7-OVA and EL4 were used as 
targets. 
mor  size in  animals  immunized  with  the  OVA  expressing 
EL4  cells  (E.GT-OVA)  was  only  7.03  cm.  Vaccination 
with 2  ￿  106 DC  pulsed with RNA  (total or polyA  +  frac- 
tion)  derived from E.GT-OVA  cells was as effective as vac- 
cination  with  5  ￿  106  of the  highly  immunogenic  E.G7- 
OVA  cells  (average  tumor  size,  7  cm).  Vaccination  with 
DC  pulsed  with  total  or polyA  +  RNA  derived from EL4 
tumor  cells  had  a  slight  protective  effect  (average  tumor 
size:  22  cm  and  19.5  cm,  respectively)  which  was  statisti- 
cally insignificant, consistent with poor to undetectable im- 
Tumor  diameter  (mm) 
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irradiated EIA 
DC+total F~G7.OVA  RNA 
DC+tota] EIA RNA 
DC+E.GT.OVA  polyA  + RNA 
DC+EIA polyA  + RNA 
DC+IVT OVA RNA 
DC4antiseNe  OVA RNA 
10  2Q  30 
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..] 
---1  ￿9  - 
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￿9 "  "1" 
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Figure 4.  A single immunization  with DC pulsed with OVA RNA in- 
duces anti-tumor immunity. DC were pulsed with either total or polyA  + 
RNA from E.G7-OVA or EL4 cells, or with IVT OVA RNA or control 
IVT ant￿9  OVA RNA in the presence of DOTAP. Mice were immu- 
nized with 2 ￿  106 DC or 5 ￿  106 irradiated E.G7-OVA or EL4 cells in- 
traperitoneally  followed by a challenge  with 2  X  10  v E.GT-OVA cells. 
Columns represent mean tumor diameter (5 mice/group) and dots repre- 
sent individual  measurements.  Mice were periodically  examined  for tu- 
mor growth and were killed when the tumor diameter  reached 3-4 cm. 
All mice were killed 35-40 d post-challenge. 
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the  primary  CTL  induction  data  (Fig.  1),  vaccination  of 
mice with IVT OVA RNA  pulsed DC provided the nmst 
effective anti tumor response (average tumor size, 3.9 cm), 
while  vaccination  with  the  control  antisense  IVT  OVA 
RNA  did not elicit a significant protective response. 
The  potency  of DC  pulsed with  tumor-derived  RNA 
was  further evaluated in the B16/F10.9  (H-2  b)  melanoma 
metastases model. The B16/F10.9 melanoma tumor is poorly 
immunogenic,  expresses low levels of MHC  class I  mole- 
cules  and  is  highly  metastatic  in  both  experimental  and 
spontaneous metastasis assay systems (26, 27). Porgador et al. 
have shown that when vaccinations are carried out after the 
removal of the primary tumor implant,  only irradiated tu- 
mor  cells  transduced  with  both  the  IL-2  and  the  H-2K  b 
genes were capable of significantly impacting the metastatic 
spread of B16/F10.9 tumor cells in the lung (26). Thus, the 
B16/F10.9  melanoma model and  the  experimental design 
used by Porgador and coworkers constitutes a stringent and 
clinically relevant experimental system to assess the efficacy 
of vaccination strategies for metastatic cancer. 
To test whether immunization with tumor RNA-pulsed 
DC  was  capable  of causing  the  regression  of preexisting 
lung metastases, primary tumors were induced by implanta- 
tion  of B16/F10.9  tumor  cells in  the  footpad.  When  the 
footpad reached 5.5-7.5 mm in diameter, the tumors were 
surgically removed  and  2  d  later  mice  were  immunized 
with irradiated B16/F10.9  cells, irradiated B16/F10.9  cells 
transduced  with  the  H-2K  6  gene  (F10.9/K1),  or  with 
RNA-pulsed DC preparations (Fig. 5).  The mice received 
a total of three vaccinations given at weekly intervals. The 
average  lung  weight  of a  normal  mouse  is  0.18-0.22  g. 
Mice immunized with  PBS  were  overwhelmed with me- 
tastases.  The  mean  lung weight  of mice  in  this  treatment 
group was 0.81  g, about three quarters of the weight con- 
tributed by the metastases which were too many to count 
(>100  nodules). A  similar metastatic load was seen in ani- 
mals  treated  with  irradiated  B16/F10.9  cells  (data  not 
shown),  which  confirms  numerous  previous  observations 
that treatment with irradiated B16/F10.9  tumor cells alone 
has no therapeutic benefit in this tumor model (25, 26). As 
also previously shown, immunization with H-2Kt'-express  - 
ing B16/F10.9  cells (F10.9/K1)  had  a  modest therapeutic 
benefit, as indicated by a statistically significant decrease in 
the  average  lung  weight  of the  animals  in  this  treatment 
group.  A  dramatic response  was  however  seen  in  animals 
treated with DC  which  were pulsed with  total RNA  de- 
rived from  F10.9  cells. The  mean  lung weight  of mice in 
this  treatment  group  was  0.37  g.  A  significant,  though 
somewhat less dramatic response was  seen  in mice treated 
with  DC  pulsed  with  polyA  +  RNA  derived from  Fl0.9 
cells (average lung weight, 0.42 g).  On the other hand,  no 
statistically significant decrease in metastatic load was  seen 
in  mice  treated  with  DC  pulsed  with  either  the  polyA- 
RNA  fraction derived from F10.9 cells or with total RNA 
isolated from EL4 tumor cells. 
Lung weight (g) 
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DC+FI0.9 polyA"  RNA  ￿9  ￿9 I  at  ￿9 
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Figure  5.  Regression  of lung  metastases in  mice  treated  with  DC 
pulsed with F10.9 tumor RNA. F10.9 tumors established  in the footpads 
of C57BL/6 mice were amputated when they reached 5.5-7.5 mm in di- 
ameter. 2 d post-amputation, and weekly thereafter, mice were vacci- 
nated intraperitoneally for a total of three times. Mice were killed 28-32 d 
post-amputation and metastatic loads were determined by measuring lung 
weights. Columns represent mean lung weight and dots represent indi- 
vidual lung weights (5  mice/gToup). The  results are representative of 
three different experiments, For more details see Materials and Methods. 
Relative  to  the  control  PBS  inmmnized group,  P values were  0.056, 
0.008, 0.032, {).841, and 0.421 for FI0.9/K1, DC+FI0.9 total RNA, 
1)C+F10.9  polyA  + RNA, DC+F10.9 polyA- RNA, and DC+EL4 to- 
tal RNA immunized mice, respectively. The overall significance of the 
study as determined by the Kruskal-Wallis  test is P = 0.034. 
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Discussion 
In this study we have  shown  that incubation of murine 
DC  with  RNA  is  an  efficient way to  introduce  antigens 
into  the  MHC  class  I  presentation  pathway.  To  confirm 
that  the  active  component  in  the  preparation was  indeed 
RNA  we used a standard procedure for RNA  isolation and 
included  extensive  incubation  with  pronase  and  DNase. 
Second,  the  activity was  enriched  in  the  polyA  +  RNA 
fraction  (Figs. 2  and  5).  Third,  in vitro synthesized RNA 
was highly effective (Figs. 1, 3, and 4). Finally, induction of 
OVA-specific CTL  was  specifically eliminated by incuba- 
tion with a complementary oligodeoxynucleotide and treat- 
ment with RNase H  (Fig. 2). 
RNA  pulsed DC stimulated cytotoxic T  cells capable of 
lysing target cells expressing endogenously processed anti- 
gen  (E.G7-OVA)  and  cells  pulsed  with  OVA  peptide 
(RMA-S/OVA-peptide)  (Figs.  2  and  5).  These  observa- 
tions strongly suggest that RNA  taken up by APC is trans- 
lated and  the  resulting protein is processed and  presented 
via the class I antigen presentation pathway. 
We used two stringent experimental systems to assess the 
antigen-presenting ability of DC incubated with RNA; in- 
duction of primary CTL  responses in vitro and regression 
of lung metastases in vivo. DC pulsed with in vitro synthe- 
sized  OVA-specific  RNA  were  capable  of stimulating  a 
primary  CTL  response  in  vitro  and  were  reproducibly 
more effective than DC pulsed with OVA peptide (Figs. 1 and 3).  Preliminary results  indicate  that human precursor- 
derived DC incubated with RNA transcribed in vitro from 
carcinoembryonic  antigen  (CEA)  eDNA are more potent 
than DC pulsed with a CEA-specific peptide in stimulating 
primary CTL in vitro  (Nair,  S.M.,  and E.  Gilboa,  unpub- 
lished data). A  possible reason why RNA-mediated sensiti- 
zation  of DC  is  more  effective  than  peptide-pulsed  DC 
could be that the  transfected RNA  serves  as a  continuous 
source  for  the  generation  of antigenic  peptides.  The  po- 
tency of RNA mediated sensitization of DC was further il- 
lustrated  by the  fact  that  DC  pulsed  with  unfractionated 
cellular  RNA  (total  or  polyA  +)  isolated  from  OVA- 
expressing  cells  were  capable  of stimulating  OVA-specific 
CTL responses, which were as effective as DC pulsed with 
OVA peptide  (Fig.  1).  Immunization of mice with RNA- 
loaded DC  elicited  a  potent  anti-tumor  response  (Figs.  4 
and  5).  As  shown  in  Fig.  5,  in  the  poorly immunogenic 
B16/F10.9  melanoma  model,  DC  incubated  with  F10.9 
tumor  RNA  were  effective  at  reducing  lung  metastases. 
This is especially remarkable in view of the fact that many 
treatments  in  this  clinically  relevant  tumor  model  have 
failed or were only marginally effective (27). 
A  potentially  unique  advantage  of using  RNA  rather 
than protein or peptides as source of unfractionated tumor 
Ag is  that  sufficient  amounts  of antigen  can be  generated 
from very small amounts of tumor tissue using PCR ampli- 
fication techniques.  Moreover, if autoimmunity becomes a 
problem (17,  18), subtractive hybridization can reduce the 
contribution of non tumor-specific antigens.  The observa- 
tion that RNA transcribed in vitro from eDNA cloned in a 
bacterial  plasmid  is effective in sensitizing DC  (Figs.  1,  3, 
and 4) allows the amplification of the antigenic content of a 
small number of tumor cells thus increasing the applicabil- 
ity  of RNA-based  vaccines  to  patients  with  low  tumor 
burdens. 
The authors  wish to thank Ms. Carla Edwards for excellent  technical  assistance in the preparation  of this 
manuscript. 
This study was supported  in part by an award from the CapCure Foundation. 
Address correspondence  to Eli Gilboa, Department of Surgery, Box 2601, Duke University Medical Center, 
Durham, NC 27710. 
Received for publication  3 May  1996 and in revised form  6June  1996. 
References 
1.  Steinman,  R.M.  1991.  The dendritic cell system and its role 
in immunogenicity. Annu. Rev. Immunol.  9:271-296. 
2.  Flamand,  V.,  T.  Somasse,  K.  Thielemans,  C.  Demanet,  M. 
Bakkus,  H. Bazin,  F. Tielemans,  O. Leo, J.  Urgain, and M. 
Moser.  1994.  Murine  dendritic cells pulsed  in vitro with tu- 
mor antigen induce tumor resistance in vivo. Eur. J. Immunol. 
24:605-610. 
3.  Hsu, F.J., C. Benike, F. Fagnoni, T.M. Liles, D. Czerwinski, 
B. Taidi, E.G. Engleman, and R. Levy. 1996. Vaccination of 
patients  with  B-cell  lymphoma  using  autologous  antigen- 
pulsed dendritic cells. Nat. Med.  2:52-58. 
4.  Paglia,  P.,  C.  Chiodoni,  M.  Rodolfo, and M.P.  Colombo. 
1996. Murine dendritic cells loaded in vitro with soluble pro- 
tein prime cytotoxic T lymphocytes against tumor antigen in 
vivo.J. Exp. Med.  183:317-322. 
5.  Porgador, A., D. Snyder, and E. Gilboa.  1996.  Induction of 
antitumor immunity using bone marrow-generated dendritic 
cells.J.  Immunol.  156:2918-2926. 
6.  Porgador, A., and E. Gilboa.  1995.  Bone marrow-generated 
dendritic cells pulsed  with a class l-restricted peptide are po- 
tent inducers of cytotoxic T  lymphocytes.J. Exp. Med.  182: 
255-260. 
7.  Ossevoort,  M.A.,  M.C.W.  Feltkamp,  K.J.H.  van  Veen, 
C.J.M. Melief,  and W.M. Kast. 1995. Dendritic cells as carri- 
ers for a cytotoxic T-lymphocyte epitope-based peptide vac- 
cine in protection against  a human papillomavirus  type  16- 
induced tumor.J. Immunother. 18:86-94. 
471  Boczkowski et al. 
8.  Mayordomo, J.I.,  T.  Zorina,  W.J.  Storkus,  L.  Zitvogel,  C. 
Celluzzi,  L.D.  Falo,  C.J.  Melief,  S.T.  Ildstad,  W.M.  Kast, 
A.B.  Deleo,  and M.T.  Lotze.  1995.  Bone marrow-derived 
dendritic  cells pulsed  with  synthetic  tumour peptides  elicit 
protective and therapeutic  antitumour immunity. Nat.  Med. 
1  :  1297-1302. 
9.  Celluzzi,  C.M., J.l. Mayordomo, W.J. Storkus,  M.T.  Lotze, 
and J.L.D.  Falo.  1996.  Peptide-pulsed dendritic  cells induce 
antigen-specific,  CTL-mediated protective tumor immunity. 
J. Exp. Mecl. 183:283-287. 
10. Finn,  O.J.  1993.  Tumor-rejection antigens  recognized by T 
lymphocytes. Curr. Opin.  lmmunol.  5:701-708. 
11. Boon, T., and P. van der Bruggen. 1996. Human tumor anti- 
gens recognized by T lymphocytes.J. Exp. Med. 183:725-729. 
12. Anichini,  A.,  R.  Mortarini,  C.  Maccalli,  P.  Squarcina,  K. 
Fleischhauer,  L. Mascheroni, and G. Parmiani.  1996.  Cyto- 
toxic  T  cells directed  to  tumor  antigens  not  expressed  on 
normal melanocytes dominate HLA-A2.1-restricted immune 
repertoire to melanoma.J. ImmunoI.  156:208-217. 
13. Johnston, J.V., A.R. Malacko,  M.T. Mizuno, P. McGowan, 
I.  Hellstrom,  K.E.  Hellstrom,  H.  Marquardt,  and L.  Chert. 
1996. B7-CD28 costimulation unveils the hierarchy of tumor 
epitopes  recognized  by  major  histocompatibility  complex 
class  I-restricted  CDS+  cytolytic  T  lymphocytes. J.  Exp. 
Mecl. 183:791-800. 
14. Shimizu,  J.,  T. Suda,  T. Yoshioka, A. Kosugi, H.  Fujiwara, 
and T. Hamaoka.  1989.  Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen- 
pulsed antigen-presenting cells. J. Immunol.  142:1053-1059. 
15. Grabbe, S.,  S. Bruvers, R.L.  Gallo, T.L.  Knisely, R.  Naza- 
reno, and R.D. Granstein. 1991. Tumor antigen presentation 
by murine epidermal cells.J. Immunol.  146:3656-3661. 
16. Zitvogel, L., J.I. Mayordomo, T.  Tjandrawan, A.B. DeLeo, 
M.R.  Clarke, M.T. Lotze, and W.J. Storkus. 1996.  Therapy 
of murine tumors with tumor peptide-pulsed dendritic cells: 
dependence on T  cells, B7 costimulation, and T  helper cell 
1-associated cytokines.J. Exp. Med.  183:87-97. 
17. Parmiani, G.  1993.  Tumor immunity as auto immunity: tu- 
mor  antigens  include  normal  self-proteins which  stimulate 
anergic peripheral T cells. Immunol.  Today. 14:536-538. 
18. Houghton, A.N. 1994. Cancer antigens: immune recognition 
of self and altered self.J. Exp. Med.  180:l-4. 
19. Martinon,  F.,  S.  Krishnan,  G.  Lenzen,  R.  Magne,  E.  Go- 
mard, J.-G. Guillet, J.-P. Levy, and P. Meulien. 1993.  Induc- 
tion of virus-specific cytotoxic T  lymphocytes in vivo by li- 
posome-entrapped mRNA. Eur.J. Immunol. 23:1719-1722. 
20.  Conry, R.M., A.F. LoBuglio, M.  Wright, L.  Sumerel, M.J. 
Pike, F. Johanning,  R.  Benjamin, D.  Lu,  and D.T.  Curiel. 
1995.  Characterization of a messenger RNA polynucleotide 
vaccine vector. Cancer Res. 55:1397-1400. 
21.  Qiu, P., P. Ziegelhoffer, J. Sun, and N.S. Yang.  1996.  Gene 
gun  delivery of mRNA in situ results  in  efficient transgene 
expression and genetic immunization. Gene Ther. 3:262-268. 
22.  Macatonia, S.E., P.M. Taylor, S.C. Knight, and B.A. Asko- 
nas. 1988. Primary stimulation by dendritic cells induces anti- 
viral proliferative and cytotoxic T  cell responses in vitro. J. 
Exp. Med.  169:1255-1264. 
23. Nair,  S.,  F.  Zhou,  R.  Reddy, L.  Huang,  and B.T.  Rouse. 
1992.  Soluble proteins delivered to  dendritic cells  via pH- 
sensitive liposomes induce primary cytotoxic T  lymphocyte 
responses in vitro.J. Exp. Med.  175:609-612. 
24. De Bruijn, M.L.H., T.N.M. Schumacher, J.D. Nieland, H.L. 
Ploegh, W.M. Kast, and C.J.M.  Melief. 1991.  Peptide load- 
ing of empty major histocompatibility complex molecules on 
RMA-S  cells  allows the  induction of primary cytotoxic T 
lymphocyte responses. Eur. J. Immunol. 21:2963-2970. 
25. Nair,  S.K.,  D.  Snyder,  and  E.  Gilboa.  1996.  Cells treated 
with  TAP-2  antisense oligonucleotides are potent  antigen- 
presenting cells  in  vitro and  in  vivo. J.  Immunol. 156:1772- 
1780. 
26. Porgador, A., M.  Feldman, and L. Eisenbach.  1989.  H-2Kb 
transfection of  B16 melanoma cells results in reduced tumori- 
genicity and metastatic competence. J.  Immunogenet.  (Oxf). 
16:291-303. 
27. Porgador,  A.,  E.  Tzehoval,  E.  Vadai,  M.  Feldman,  and  L. 
Eisenbach.  1995.  Combined  vaccination with  major histo- 
compatibility class I and interleukin 2 gene-tranduced mela- 
noma cells synergizes the cure ofpostsurgical established lung 
metastases.  Cancer Res. 55:4941-4949. 
28. Ljunggren,  H.-G.,  and K.  Karre.  1985.  Host  resistance di- 
rected selectively against H-2-deficient lymphoma variants: 
analysis of the mechanism.J. Exp. Med.  162:1745-1759. 
29. Moore, M.W., F.R. Carbone, and M.J. Bevan.  1988.  Intro- 
duction of soluble protein into the class I pathway of antigen 
processing and presentation. Cell. 54:777-785. 
30. Chomczynski, P., and N.  Sacchi.  1987.  Single-step method 
of RNA isolation by acid guanidinium thiocyanate-phenol- 
chloroform extraction. Anal. Biochem. 162:156-159. 
31. Donis-Keller, H.  1979.  Site specific enzymatic cleavage of 
RNA. Nucleic Acids Res. 7:179-192. 
32.  Walker, C., M. Selby, A. Erickson, D. Cataldo, J.-P. Valensi, 
and G. van Nest.  1992.  Cationic lipids direct a viral glyco- 
protein into the class I major histocompatibility complex an- 
tigen-presentation pathway.  Pro& Natl.  Acad. Sd.  USA.  89: 
7915-7918. 
33. Rotzschke, O., K. Falk, S. Stevanovic, G. Jung,  P. Walden, 
and H.G. Rammensee.  1991. Exact prediction of a natural T 
cell epitope. Eur. J. Immunol. 21:2891-2894. 
34. Volgrnann, T., A. Klein-Struckmeier, and H. Mohr.  1989. A 
fluorescence-based assay for quantitation oflymphokine-acti- 
vated killer cell activity.J. Immunol. Methods. 119:45-51. 
35. Carbone,  F.R.,  M.W.  Moore, J.M.  Sheil, and M.J.  Bevan. 
1988.  Induction of cytotoxic T  lymphocytes by primary in 
vitro stimulation with peptides.J. Exp. Med.  167:1767-1779. 
472  RNA-pulsed Dendritic Dells 